Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Gene therapy firm launches with collaboration

by Shi En Kim
June 9, 2023 | A version of this story appeared in Volume 101, Issue 19

 

Kate Therapeutics, a gene therapy company, has emerged from stealth with $51 million in series A financing as well as a licensing collaboration. Kate aims to tackle muscle and heart diseases, primarily with its flagship platform of designing adeno-associated virus capsids for the selective delivery of genetic cargo to muscle tissues. The start-up has licensed its investigational gene therapy for myotubular myopathy to the Japanese firm Astellas Pharma.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.